Navigation Links
Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors
Date:8/31/2011

SAN FRANCISCO, Aug. 31, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced the publication of clinical data on its lead product JX-594 in the journal Nature. For the first time in humans, an oncolytic virus was shown to reproducibly infect, replicate and express transgene products within cancer tissue after intravenous infusion.  Normal tissues were not significantly affected clinically, underscoring the designed selectivity of JX594 for malignant tissue and safety of the product.

"Our platform technology opens up the possibility of selectively expressing multiple transgene products with complementary mechanisms of action at high concentration in tumors systemically. This is a first in medical history," said David Kirn, M.D., president and chief executive officer of Jennerex. "We believe it will take truly innovative, multi-mechanistic approaches to significantly prolong survival, and to potentially cure patients with metastatic solid tumors. JX-594, with its ability to reach tumors systemically after IV infusion, coupled with its three complementary mechanisms of action, represents a bold new approach to the treatment of metastatic cancers."

Dr. Kirn continued, "We look forward to working with our partners on the clinical development of JX-594 in liver, colorectal and other cancer types. We're particularly excited about the TRAVERSE trial, a global, randomized, controlled Phase 2b clinical trial of JX-594 in patients with hepatocellular carcinoma (liver cancer) having failed sorafenib (Nexavar®) treatment, which we plan to initiate this year."

JX-594 replication and engineered transgene expression within solid tumors was evaluated on a Phase 1 dose-escalation trial of intravenous infusion of JX-594. Twenty-three patients with advanced, treatment-refractory
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... BARCELONA, Spain , April 27, 2015  Together ... during the 3rd ESTRO Forum in Barcelona ... Hope, a nonprofit organization with the mission to improve ... Radiating Hope believes that no patient should ... is not affordable. Consequently, it cooperates with hospitals and ...
(Date:4/24/2015)... 24, 2015 Leading Regenerative Veterinary ... its allogeneic stem-cell product development program and changes ... the corporate strategic direction. , “I am extremely ... stem cell development program has been kicked into ... manufacturing facility and hiring of our new Director ...
(Date:4/24/2015)... , April 24, 2015  Navitas Life Sciences is delighted ... Head of Clinical and Regulatory Services. Shalabh is a proven ... co-founder and CEO of Kinapse, as well as a Strategy ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... commented "I am delighted to welcome Shalabh into this ...
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
Breaking Biology Technology:Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3
... ... learn about the oldest buildings on earth and a “fascinatingly weird” ancient culture. ... (PRWEB) June 11, 2010 -- ... website to provide a simple introduction to megalithic architects in Frequently Asked Question format. ...
... ... in clinical research, key issues around open source technology are highlighted at leading industry events. ... Washington, DC (PRWEB) June ... meeting of the Drug Information Association (DIA). The DIA Annual Meeting is the ...
... , DENVER , June 11 On Wednesday June ... Meeting to discuss patient-focused clinical research systems in the age of personalized cancer ... at North Shore Hematology/Oncology Associates in East Setauket, NY and ... , , , ...
Cached Biology Technology:New tool for exploring the ancient world. 2Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 2Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 3Pharmatech Oncology to Present at 46th Annual DIA Meeting 2Pharmatech Oncology to Present at 46th Annual DIA Meeting 3
(Date:3/26/2015)... , March 26, 2015 ... family, social, recreation and athletic club, today announced it ... to allow freedom of movement for members and staff, ... "Following a comprehensive process, we selected FST,s IMID Access ... and convenience for our members and staff, in addition ...
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... North American stilt-legged horses have found a new place ... in the open access journal PLoS Biology. In the ... DNA to argue that the Hippidion genus is younger ... American endemics, not Asian emigres. Their analysis has also ...
... technique aimed at directly controlling the expression of genes by ... lead to drugs for the treatment or cure of many ... every disease starts at the level of malfunctioning gene expression, ... professor of pharmacology and biochemistry. "This is an approach that ...
... grass, not for fun but for fuel. Burning grass ... for decades. But not in the United States. , ... energy-efficient, environmentally friendly and sustainable, says a Cornell University ... be produced and pelleted by farmers and burned in ...
Cached Biology News:Ancient DNA helps clarify the origins of two extinct New World horse species 2Gene silencing technique offers new strategy for treating, curing disease 2Grass makes environmentally friendly biofuel 2
... precision, more user-friendliness and absolute reliability united ... definition of the Mastercycler ep system. In ... has been developing dynamically. The same applies ... To keep pace with these technological ...
... This kit is designed for easy ... The protocol allows for successful transformation simply ... kit reagents with cultured yeast cells. No ... washing, are required. The kit is particularly ...
... LabX light balance makes your life easier. It offers ... and management for one balance. *Instruments supported: ... AX, MX, UMX, AG, XS, XP, PR, SR, PG-S, ... *Job management: User ...
... Form: powder ,Components g/500 ... 2.5 ,Sodium chloride 2.5 ,Agar ... citrate 0.250 ,IPTG 0.025 ,Kanamycin ... is a complete growth medium ...
Biology Products: